1Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal of clinical trials. J Clin Psychiatry, 1997, 58(Suppl 10) : 7
2Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry, 1997, 58 (Suppl 10) : 13
3Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the trearment of schizophrenia and scbizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry, 1997, 154 : 457
4Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatmentemergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry, 1997, 154: 1248
5Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the scute treatment of schizophrenia. J Clin Psychiatry, 1997, 58 : 205
6Kim HS, Kamboh MI. Genetic polymorphisms of apolipoproteins A -,E and H in Koreans. Hum Hered, 1998, 48(6): 313-317
7Gushiken FC. Primary antiphospholipid antibody syndrome with mutations in the phospholipid binding domain of beta2 - glycoprotein I. Am J Hematol, 2000, 65(2): 160- 165
8Kamboh MI, Mehdi H. Genetics of apolipoprotein H(beta2-glycoprotein Ⅰ) and anionic phospholipid binding. Lupus, 1998, 7(suppl 2):S10 - S13
9Francisca C, Gushiken. Polymorphism of beta 2 - glycoprotein I at codons 306 and 316 in patients with systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum, 1999, 42(6): 1189-1193
10Balasubramanian K, Killion JJ, Schroit AJ. Estimation of plasma beta 2- glycoprotein I levels by competitive ELISA. Thromb Res, 1998, 92(2): 91 - 97
